Genelux (GNLX) Total Current Liabilities (2022 - 2026)
Genelux's (GNLX) quarterly Total Current Liabilities came in at $7.3 million in Q1 2026, up 16.82% quarter-over-quarter from $6.2 million in Q4 2025.
Genelux (GNLX) Total Current Liabilities (2022 - 2026) Analysis & Trends
Genelux's Total Current Liabilities history runs 5 years deep, the most recent figure standing at $7.3 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.2 million, down 9.82% from the prior year.
- Total Current Liabilities improved to $7.3 million in Q1 2026 per GNLX's latest filing, from $6.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $31.6 million in Q4 2022 and bottomed at $5.1 million in Q3 2025.
- The 5-year median for Total Current Liabilities is $6.9 million (2024), against an average of $9.0 million.
- Across the five-year window, Total Current Liabilities tumbled 79.28% in 2023 and advanced 20.42% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $31.6 million in 2022, then tumbled by 79.28% to $6.6 million in 2023, then advanced by 5.32% to $6.9 million in 2024, then slipped by 9.82% to $6.2 million in 2025, then advanced by 16.82% to $7.3 million in 2026.
- Per Business Quant, the three latest GNLX Total Current Liabilities figures stand at $7.3 million (Q1 2026), $6.2 million (Q4 2025), and $5.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 289.60 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 7.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.27 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Jun 30, 2025 | 6.99 Mn |
| Dec 31, 2024 | 6.90 Mn |
| Sep 30, 2024 | 5.56 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 6.55 Mn |
| Sep 30, 2023 | 8.76 Mn |
| Dec 31, 2022 | 31.63 Mn |